Trial Profile

A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triheptanoin (Primary)
Indications Huntington's disease
Focus Therapeutic Use
Acronyms TRIHEP3

Most Recent Events

22 Sep 2021 Results from NCT02453061 and other study assessing association of triheptanoin with clinical stability (UHDRS) and decreased caudate atrophy in Huntington disease patients, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
24 Aug 2021 Status changed from active, no longer recruiting to completed.
20 Dec 2020 This trial has been completed in France, according to European Clinical Trials Database record.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial